TY - JOUR T1 - LesionQuant for assessment of MRI in multiple sclerosis - a promising supplement to the visual scan inspection JF - medRxiv DO - 10.1101/2020.04.01.20048249 SP - 2020.04.01.20048249 AU - Synne Brune AU - Einar A. Høgestøl AU - Vanja Cengija AU - Pål Berg-Hansen AU - Piotr Sowa AU - Gro O. Nygaard AU - Hanne F. Harbo AU - Mona K. Beyer Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/04/06/2020.04.01.20048249.abstract N2 - Background and goals Multiple sclerosis (MS) is a central nervous system inflammatory disease where magnetic resonance imaging (MRI) is an important tool for diagnosis and disease monitoring. Quantitative measurements of lesion volume, lesion count, distribution of lesions and brain atrophy have a potentially significant value for evaluating disease progression. We hypothesize that utilizing software designed for evaluating MRI data in MS will provide more accurate and detailed analyses compared to the visual neuro-radiological evaluation.Methods A group of 56 MS patients (mean age 35 years, 70% females and 96% relapsing-remitting MS) was examined with brain MRI one and five years after diagnosis. The T1 and FLAIR brain MRI sequences for all patients were analysed using the LesionQuant(LQ) software. These data were compared with data from structured visual evaluations of the MRI scans performed by a neuro-radiologist, including assessments of atrophy and lesion count. Correlations with clinical tests like the timed 25-foot walk test (T25FT) were performed to explore additional value of LQ analyses.Results Lesion count assessments by LQ and by the neuro-radiologist were significantly correlated one year (cor=0.92, p=2.2×10−16) and five years (cor=0.84, p=2.7×10−16) after diagnosis. LQ detected a reduction in whole brain percentile >10 in 10 patients across the time-points, whereas the neuro-radiologist assessment identified six of these. The neuro-radiologist additionally identified five patients with increased atrophy in the follow-up period, all of them displayed decreasing low whole brain percentiles (median 11, range 8-28) in the LQ analysis. Significant positive correlation was identified between lesion volume measured by LQ and test performance on the T25FT both at one year and five years after diagnosis.Conclusion For the number of MS lesions at both time-points, we demonstrated strong correlations between the assessments done by LQ and the neuro-radiologist. Lesion volume evaluated with LQ correlated with T25FT performance. LQ-analyses were more sensitive in capturing brain atrophy than the visual neuro-radiological evaluation. In conclusion, LQ seems like a promising supplement to the evaluation performed by neuro-radiologists, providing an automated tool for evaluating lesions and brain volume in MS patients in both a longitudinal and cross-sectional setting.Competing Interest StatementS. Brune has received honoraria for lecturing from Biogen and Novartis. E. A. Høgestøl has received honoraria for lecturing from Biogen, Merck and Sanofi-Genzyme. P. Berg-Hansen has received advisory board and/or speaker honoraria for lecturing from Biogen, Novartis, Merck, UCB and Teva. P. Sowa has received honoraria for lecturing and travel support from Merck. H.F Harbo has received travel support, honoraria for advice or lecturing from Biogen Idec, Sanofi-Genzyme, Merck, Novartis, Roche, and Teva and an unrestricted research grant from Novartis and Biogen. M. K. Beyer has received honoraria for lecturing from Novartis and Biogen Idec, Merck AB, Roche Norge and Sanofi Genzyme. G.O. Nygaard reports no disclosures.Funding StatementThe project was supported by grants from The Research Council of Norway (NFR, grant number 240102 and 223273) and the South-Eastern Health Authorities of Norway (grant number 257955 and 2019111).Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDue to the sensitive nature of the data, they can not be freely downloaded from a website. Please contact the Authors if you wish to ask for Access to these data, or want to collaborate With us. ER -